As reported in Reuters and in GEN, Teva Pharmaceuticals submitted a BLA for its drug XM02. This biosimilar is already approved in Europe. It would compete against Amgen's Neupogen and Neulasta. Amgen had sales for these two drugs of approximately $4.64 billion in 2009. If approved in the US, the proposed trade name for the new Teva drug is Neutroval.
Posted by Bruce Lehr Feb 3, 2010
Comments